Follow Us:
OB/GYNs, Primary Care Physicians, Nurse Practitioners, Physician's Assistants, Endocrinologists
Women's Health, Vulvovaginal atrophy, Genitourinary Syndrome of Menopause
Dr. Simon earned his bachelor's degree from Washington University in St. Louis and his medical degree from Rush Medical College in Chicago. He completed an internship and residency in obstetrics and gynecology at The George Washington University Hospital and a fellowship in endocrinology and infertility at Harbor-University of California, Los Angeles Medical Center.
Dr. Goldstein has been involved with sexual dysfunction research since the late 1970's. His interests include penile microvascular bypass surgery, surgery for dyspareunia, sexual health management post cancer treatment, physiologic investigation of sexual function in men and women, and diagnosis and treatment of sexual dysfunction in men and women. Dr. Goldstein has authored more than 350 publications in the field of sexual dysfunction, and edited books on erectile dysfunction and on women's sexual health. He is also Editor-in-Chief of Sexual Medicine Reviews and past Editor-in-Chief of The Journal of Sexual Medicine, official journals of the International Society for Sexual Medicine, its regional affiliate societies, and the International Society for the Study of Women's Sexual Health. Dr. Goldstein is Director of Sexual Medicine at Alvarado Hospital, Clinical Professor of Surgery at University of California at San Diego and Director of San Diego Sexual Medicine where he maintains his clinical practice.| 1. | Discuss how the science of Intracrinology and DHEA relates to the physiologic, histologic and morphologic changes associated with menopause and treatment of dyspareunia/Vulvovaginal atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM), and potentially Hypoactive Sexual Desire Disorder (HSDD) | 2. | Summarize key data for new, intracrine-based therapy for dyspareunia |
| 3. | Discuss potential therapies in development for the treatment of dyspareunia and Hypoactive Sexual Desire Disorder (HSDD) | 4. | Summarize key safety and efficacy information on traditional therapies for Vulvovaginal atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) |
| 1. | Discuss how the science of Intracrinology and DHEA relates to the physiologic, histologic and morphologic changes associated with menopause and treatment of dyspareunia/Vulvovaginal atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM), and potentially Hypoactive Sexual Desire Disorder (HSDD) |
| 2. | Summarize key data for new, intracrine-based therapy for dyspareunia |
| 3. | Discuss potential therapies in development for the treatment of dyspareunia and Hypoactive Sexual Desire Disorder (HSDD) |
| 4. | Summarize key safety and efficacy information on traditional therapies for Vulvovaginal atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) |
| Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |